Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial - Report - MDSpire
Advertisement
Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial
Efficacy and Safety of Benvitimod vs Halometasone in Moderate-to-Severe Chronic Hand Eczema
Overview
This randomized trial compared benvitimod cream to halometasone cream in patients with moderate-to-severe chronic hand eczema (CHE). Both treatments showed similar efficacy, but benvitimod demonstrated a more favorable safety and tolerability profile.
Background
Chronic hand eczema is a persistent inflammatory skin condition that significantly impairs quality of life and imposes socioeconomic burdens. Topical corticosteroids are the standard treatment but have limited evidence of efficacy and are often refused due to side effects and relapse risk. Benvitimod, a novel nonsteroidal topical agent targeting the aryl hydrocarbon receptor, has shown promise in treating inflammatory skin diseases and may offer a safer alternative for CHE management.
Data Highlights
Parameter
Benvitimod Group
Halometasone Group
Duration of Treatment
8 weeks
8 weeks
Application Frequency
Twice daily
Twice daily
Primary Endpoint
Achievement of "clear" or "almost clear" with ≥2 point PGA improvement
Same
Efficacy
Similar to halometasone
Similar to benvitimod
Safety Profile
More favorable, better tolerability
Less favorable compared to benvitimod
Key Findings
Benvitimod cream demonstrated efficacy comparable to halometasone cream in treating moderate-to-severe CHE.
Benvitimod showed a more favorable safety and tolerability profile than halometasone.
Both treatments were applied twice daily for 8 weeks with concurrent moisturizer use and avoidance of irritants.
Patients achieving treatment success were monitored for relapse up to 24 weeks without additional CHE treatments.
Benvitimod represents a promising nonsteroidal alternative for patients who are refractory to or refuse corticosteroids.
Clinical Implications
Benvitimod cream may be considered a viable and safer alternative to topical corticosteroids for moderate-to-severe CHE, especially for patients concerned about corticosteroid side effects or long-term use. Its favorable safety profile supports its use for maintenance therapy and potentially improves patient adherence. Clinicians should consider benvitimod in treatment plans where corticosteroid use is limited or contraindicated.
Conclusion
Benvitimod offers comparable efficacy to halometasone with improved safety in moderate-to-severe chronic hand eczema, representing a novel therapeutic option. Further studies may solidify its role in long-term management of CHE.
References
Wang et al. 2023 -- Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Moderate-to-Severe Chronic Hand Eczema
